Syros Pharmaceuticals, Inc. booked $9.9M in FY2023 revenue, contracting 33% year over year — slower than 77% of Healthcare companies we track, at a -1656.3% net margin.
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.